Exploring the effect of post-exercise blood biomarkers in healthy volunteers on skin cancer cell lines.
Not Applicable
- Conditions
- Basal Cell CarcinomaCutaneous squamous cell carcinomaCancer - Non melanoma skin cancer
- Registration Number
- ACTRN12624000966594
- Lead Sponsor
- niversity of Canberra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Participants will be recreationally active, healthy adults, 25-40 years old.
Exclusion Criteria
Participants must not have any prior or current history of or being
treated for any chronic illness or cancer, including any type of skin cancer. All participants with current or previous history of chronic
illness or cancer including cancer will be excluded from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of exercised serum on cell viability on keratinocyte cancer cell lines[Cell proliferation assay 3 repeated trials (to assess for replicability), 4 weeks in between each trial. Assessed at each of the 3 repeated trials conducted at week 1, 4 and 8.<br>];Effect of exercised serum on apoptosis on keratinocyte cancer cell lines[Apopercentage assay 3 repeated trials (to assess for replicability), 4 weeks in between each trial. Assessed at each of the 3 repeated trials conducted at week 1, 4 and 8.]
- Secondary Outcome Measures
Name Time Method Characterizing changes in immune biomarkers (Interleukin-6, ) after exercise[Enzyme-linked immunosorbent assays (ELISA kits) 3 repeated trials (to assess for replicability), 4 weeks in between each trial. Assessed at each of the 3 repeated trials conducted at week 1, 4 and 8.];Characterizing changes in immune markers (Natural Killer Cells, T cells activation and proliferation)[IL-15 Enzyme-linked immunosorbent assays (ELISA kits) 3 repeated trials (to assess for replicability), 4 weeks in between each trial. Assessed at each of the 3 repeated trials conducted at week 1, 4 and 8.]